Oxygen Treatment Lowers Chemoreceptor Activity but Does Not Improve Glucose Metabolism in Diabetes
Researchers at the University of Missouri are investigating new therapies that target specific cells involved in cardiovascular and metabolic disorders, including hypertension and type 2 diabetes. Their focus is on chemoreceptors, which monitor oxygen levels in the body, and whether adjusting these levels could affect chemoreceptor activity and consequently, cardiovascular and metabolic health.
Exploring Hyperoxia as a Potential Therapy
Jacqueline Limberg, the study’s lead author and an associate professor of nutrition and exercise physiology, explains, “Research in rats has shown that removing overactive chemoreceptors can enhance conditions like high blood pressure and elevated blood sugar. Instead of permanent removal, we hypothesized that high oxygen levels might reduce or ‘shut off’ chemoreceptor activity, potentially improving health outcomes in humans.”
The study involved two groups: 17 participants with type 2 diabetes and 20 healthy participants as a control group. They discovered that peripheral chemoreceptors were highly active in diabetic patients, with activity correlating with higher blood sugar levels.
Findings from the Hyperoxia Experiment
During hyperoxia, where participants were exposed to elevated oxygen levels, the activity of chemoreceptors decreased. Additionally, heart rate, blood pressure, and respiratory rate also fell. However, these improvements were consistent across both diabetic and non-diabetic groups. More importantly, hyperoxia had no impact on glucose tolerance or insulin sensitivity.
Implications and Future Research
According to Camila Manrique-Acevedo, a co-author and professor of medicine, “Our study aimed to understand how peripheral chemoreceptors influence the cardiovascular and metabolic effects of type 2 diabetes. The findings demonstrate that one session of hyperoxia does not provide immediate improvements in metabolic function. This knowledge directs our focus towards exploring other therapies that may hold more promise for treating type 2 diabetes.”
Conclusion
The research, published in The Journal of Physiology, highlights the complexity of treating diabetes and the limitations of hyperoxia as a definitive treatment method. It underscores the need for further investigation into alternative therapies that could target chemoreceptors and improve glucose metabolism.
Reference: “Role of the peripheral chemoreceptors in cardiovascular and metabolic control in type 2 diabetes” by Jacqueline K. Limberg, Elizabeth P. Ott, Aubrey M. Pipkins, Eric C. Lis, Anna M. Gonsalves, Jennifer L. Harper, and Camila Manrique-Acevedo, 28 August 2024, The Journal of Physiology.
DOI: 10.1113/JP286975
Jacqueline Limberg is an associate professor of nutrition and exercise physiology in the College of Agriculture, Food and Natural Resources. Camila Manrique-Acevedo is a professor of medicine and the Thomas W. Burns, MD, Distinguished Professor in Diabetes at the School of Medicine. She also serves as a NextGen Precision Health investigator.
If you found this article insightful, please don’t hesitate to share your thoughts, subscribe to our newsletter, or share on social media to stay updated with the latest in health and science.
